Trump's remarks came a day before the Fed was set to announce its next decision on interest rates.Politicsread more
The U.S. and China have imposed tariffs on billions of dollars' worth of one another's goods since the start of 2018.Traderead more
More and more American firms are calling for the Trump administration to resolve its conflict with China.World Economyread more
In a tweet, Trump said that he and Xi "had a very good telephone conversation," and that "our respective teams will begin talks prior to our meeting."Politicsread more
China is reducing support for its electric carmakers a move experts and industry insiders warn could lead to consolidation and waning investor appetite. But some of the...Technologyread more
Is your CEO on the list? Glassdoor has the results.Power Playersread more
Joseph Gaspar, the chief financial officer at Elbit Systems, said M&A among firms in the sector began to pick up pace in the 1980s and looks set to continue.Paris Air Showread more
Stocks in Asia rose on Wednesday following positive developments overnight on the U.S.-China trade front.Asia Marketsread more
The U.S. Department of Defense has hit back at Russian officials who have criticized a U.S. plan to deploy more troops to the Middle East.World Politicsread more
Signs of companies moving out of Hong Kong have emerged, members of the business community told CNBC following massive protests in the city. But one analyst said Hong Kong's...China Politicsread more
Sen. Josh Hawley, a well-known tech critic, introduced legislation on Wednesday that would remove the immunity big technology companies receive for user-posted content under...Technologyread more
Michael Pearson, chairman and CEO of Valeant Pharmaceuticals, won't pay too much for Salix Pharmaceuticals, which earlier this week received a competing offer from Endo International, billionaire investor Bill Ackman told CNBC on Friday.
Ackman's Pershing Square Capital Management disclosed Monday a 4.9 percent stake in Canada-based Valeant, which had sought his help last year in its failed bid to buy Botox-maker Allergan. After a contentious seven months, Allergan agreed in November to a $66 billion buyout from Irish rival Actavis.
"I know Mike Pearson very well. I worked with him for a year. He's the most disciplined buyer of companies. He's not going to overpay for Salix," Ackman said in a "Squawk Box " interview, which focused on a reported FBI investigation of Ackman's positions on Herbalife.
Dublin-based specialty drugmaker Endo on Wednesday made an $11 billion cash and stock offer for Salix, which had already agreed to a $10 billion cash offer from Valeant. Salix said it would consider the Endo bid.
"In order for them to take the Endo transaction they have to walk away from an all-cash deal," Ackman said. "If you think Valeant is getting it on the cheap, then you should buy Valeant stock, which is what we did. We think Valeant stock is very cheap."
Raleigh, North Carolina-based Salix makes medicines for gastrointestinal disorders, including Pepcid and Zegerid.
Valeant, Salix and Endo did not immediately respond to CNBC requests for comment.
—Reuters contributed to this report.